Get the Stockscreener App
0.6207
2.59%
-0.0165
Immunic Inc stock is traded at $0.6207, with a volume of 1.32M.
It is down -2.59% in the last 24 hours and down -6.61% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.6372
Open:
$0.672
24h Volume:
1.32M
Relative Volume:
0.95
Market Cap:
$74.67M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.2942
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
+21.66%
1M Performance:
-6.61%
6M Performance:
-14.65%
1Y Performance:
-43.06%
1-Day Range:
$0.613
$0.6836
1-Week Range:
$0.5092
$0.6836
52-Week Range:
$0.5062
$1.39
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.6208 | 76.65M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.04 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.71 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.07 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.66 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.78 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic (NASDAQ:IMUX) Shares Up 9.3% – Should You Buy? - Defense World
Immunic appoints Duane Nash as CEO of new subsidiary Gliomic, updates executive agreements - Investing.com Australia
Immunic appoints Duane Nash as CEO of new subsidiary Gliomic, updates executive agreements By Investing.com - Investing.com South Africa
Immunic (IMUX) Has a New Rating from Chardan Capital - The Globe and Mail
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies - GlobeNewswire Inc.
Immunic Earnings Notes - Trefis
Gainers Report: Will Immunic Inc 10VA stock benefit from mergers2025 Fundamental Recap & Reliable Breakout Forecasts - moha.gov.vn
Will Immunic Inc. (10VA) stock benefit from mergersJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Will Immunic Inc. (10VA) stock extend growth storyWeekly Trade Summary & AI Based Buy/Sell Signal Reports - DonanımHaber
Why Immunic Inc. (10VA) stock stays resilientQuarterly Profit Review & Daily Chart Pattern Signals - DonanımHaber
Will Immunic Inc. stock outperform international peersStock Surge & Intraday High Probability Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Immunic (IMUX) - The Globe and Mail
Immunic Inc (IMUX)’s stock performance: a year in review - uspostnews.com
Immunic launches public offering of warrants to fund clinical trials; shares down - MSN
683 Capital Management LLC Reduces Stake in Immunic, Inc. $IMUX - Defense World
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Analysts - Defense World
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Analysts - MarketBeat
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Immunic Inc - GuruFocus
How does Immunic Inc (IMUX) change from a tortoise to a hare? - setenews.com
Immunic’s long-term treatment hope for multiple sclerosis – ICYMI - Proactive financial news
Operating income of Immunic, Inc. – HAM:10VA - TradingView
Will Immunic Inc. stock deliver better than expected guidanceRisk Management & Real-Time Buy Signal Alerts - Newser
How risky is Immunic Inc. stock nowJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Will Immunic Inc. (10VA) stock return to pre crash levels2025 Fundamental Recap & Consistent Profit Alerts - Newser
How supply chain issues affect Immunic Inc. stockMarket Activity Recap & Weekly Sector Rotation Insights - Newser
Why Immunic Inc. (10VA) stock is a strong analyst pickPortfolio Gains Summary & Technical Pattern Alert System - Newser
Can Immunic Inc. (10VA) stock withstand sector downturnsTrade Exit Summary & Real-Time Buy Zone Alerts - Newser
Is Immunic Inc. stock near bottom after declineOil Prices & Daily Momentum Trading Reports - Newser
How Immunic Inc. stock performs in stagflation2025 Investor Takeaways & Target Return Focused Picks - Newser
Immunic marks International Day of Persons with Disabilities with hope for MS sufferers - Proactive financial news
What consensus target says about Immunic Inc. (10VA) stockWeekly Risk Summary & Safe Capital Growth Stock Tips - Newser
Why Immunic Inc. stock is considered a top pickPortfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Will Immunic Inc. (10VA) stock outperform Dow JonesTrade Analysis Summary & Technical Confirmation Trade Alerts - Newser
IMUX stock touches 52-week low at $0.92 amid market challenges - MSN
Will Immunic Inc. (10VA) stock outperform global peers2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
Immunic (IMUX) Stock Analysis Report | Financials & Insights - Benzinga
B. Riley Has Bullish Estimate for Immunic FY2025 Earnings - MarketBeat
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Sahm
What is B. Riley’s Forecast for Immunic FY2025 Earnings? - Defense World
What is B. Riley’s Estimate for Immunic Q1 Earnings? - Defense World
B. Riley Forecasts Immunic's Q1 Earnings (NASDAQ:IMUX) - MarketBeat
Immunic announces attendance at upcoming Evercore ISI Healthcare Conference | NASDAQ:IMUX - Proactive financial news
Immunic (NASDAQ: IMUX) to present at 8th Evercore ISI Healthcare Conference on Dec. 4 - Stock Titan
Immunic Inc (IMUX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Analysts Offer Predictions for Immunic FY2025 Earnings - MarketBeat
Immunic FY2025 EPS Boosted by Brookline Capital Management - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Chardan Capital - Defense World
Immunic Inc. (IMUX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Equities Analysts Issue Forecasts for Immunic Q1 Earnings - MarketBeat
How Immunic Inc. stock performs in weak economyJuly 2025 WrapUp & Entry Point Strategy Guides - newser.com
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunic Inc Stock (IMUX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):